The following studies have contributed to our Opioid Dependence datasets.
Study 03 – Molecular Genetics of Heroin Dependence in China
Investigators: Ming Tsuang, Steve Faraone Status: Available at NIDA Repository and dbGaP dbGaP Accession ID: phs001213.v2.p1 NIDA Release Date: March 2009 dbGaP Release Date: 04/16/2020 SPECIFIC AIMS: Although the available data strongly suggest that a substantial component of the etiology of drug dependence is mediated by gene expression in the central nervous system (Tsuang et al., 1996; Tsuang et al.,...
Study 05 – Addictions, Genotypes, Polymorphisms, and Function
Investigator: Mary Jeanne Kreek Status: Available at NIDA Repository and dbGaP dbGaP Accession ID: phs001109.v1.p1 NIDA Release Date: February 2008 dbGaP Release Date: 08/29/2016 Abstract: Information on this diagnostic instrument is provided as documentation for the NIDA consortium, and is to be used for informational purposes only. Further information about the SCID can be found at the SCID website. Drug...
Study 08 – Mu Opioid Receptor Gene in Heroin Addicts
Investigator: Lei Yu Status: Available at NIDA Repository NIDA Release Date: February 2008 Abstract: Addiction to heroin is a major social problem, affecting over a million people in the United States. In the body and brain, heroin is hydrolyzed to morphine, which acts at the mu opioid receptor and results in a euphoric effect, thus conferring the reinforcing properties of...
Study 14 – Genome-Wide Analysis for Addiction Susceptibility Genes
Investigator: Herbert Lachman Status: Available at NIDA Repository and dbGaP dbGaP Accession ID: phs001266.v2.p1 NIDA Release Date: April 2010 dbGaP Release Date: 09/14/2020 Abstract (adapted from applicant's abstract): This is an R01 application for funding to identify chromosomal markers linked to drug dependence. The use of illicit, highly addictive drugs is a major public health and legal problem in the...
Study 17 – Opioid Dependence
Investigator: Wade Berrettini Status: Available at NIDA Repository and dbGaP NIDA Release Date: April 2010 Abstract: This application proposes a genetic study of the mu opioid receptor gene (OPRM1) as a predictor of risk for opioid dependence (OD). Pharmacologic, genetic and behavioral studies suggest that risk for OD may be mediated in part by sequence variation in OPRM1 gene. ...
Study 18 – Opioid Dependence: Candidate Genes and G x E Effects
Investigator: Elliot Nelson Status: Available at NIDA Repository and dbGaP NIDA Release Date: August 2013 Abstract: This project seeks to achieve a better understanding of the interaction between genetic and environmental factors have been demonstrated to be associated with risk for opioid dependence. The design incorporates childhood trauma history as a risk modifying variable in a case-control genetic association study...
Study 24 – START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies (START); CTN-00027
Investigators: Wade Berrettini, M.D., Ph.D., C. Lindsay DeVane, PharmD. Status: Available at NIDA Repository, dbGaP and Clinical Trials Network dbGaP Accession ID: phs001135.v2.p1 NIDA Release Date: August 2013 dbGaP Release Date: 09/14/2020 Abstract: This proposal outlines a supplementary pharmacogenetics component to the NIDA START trial. Patients participating in START will be offered the opportunity to volunteer for a genetics study...
Study 39 – Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT); CTN-0097
CTN-0097: Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT) Investigator: Adam Bisaga, M.D. Release Date: TBA View Study in Clinical Trials Network Site Objective: The primary goal of this hybrid effectiveness-implementation study is to determine whether the Rapid method of initiating treatment with extended-release injection naltrexone (XR-NTX) is...
Study 40 – Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY); CTN-0098
CTN-0098: Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY) Investigator: Gavin Bart, M.D., Ph.D. Release Date: TBA View Study in Clinical Trials Network Site Objective: The primary objective of this study is to define and refine best practices for hospital-initiated treatment of opioid use disorder (OUD) and post-discharge treatment engagement by NIDA/CTNs expertise in hospital-based addiction care. Engagement...
Study 41 – Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; CTN-0100
CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy Investigators: Edward Nunes, M.D., John Rotrosen, M.D., & Roger Weiss, M.D. Release Date: TBA View Study in Clinical Trials Network Site Objective: Although medications for opioid use disorder (MOUD) are highly effective, most studies show > 50% dropout at 3–6 months, and dropout carries a high risk of...